Comparative Proteomics Reveals Dysregulated Mitochondrial O

Subscriber access provided by UNIV OF NEBRASKA - LINCOLN

Article

Comparative Proteomics Reveals Dysregulated Mitochondrial O-GlcNAcylation in Diabetic Hearts Junfeng Ma, Partha Sarathi Banerjee, Stephen A Whelan, Ting Liu, An-Chi Wei, Genaro RamirezCorrea, Mark E McComb, Catherine E Costello, Brian O'Rourke, Anne Murphy, and Gerald W. Hart J. Proteome Res., Just Accepted Manuscript • DOI: 10.1021/acs.jproteome.6b00250 • Publication Date (Web): 23 May 2016 Downloaded from http://pubs.acs.org on May 25, 2016

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Journal of Proteome Research is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 42

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Journal of Proteome Research

Comparative Proteomics Reveals Dysregulated Mitochondrial O-GlcNAcylation in Diabetic Hearts

Running title: Mitochondrial O-GlcNAcylation in diabetic hearts

Junfeng Ma†, Partha Banerjee†, Stephen A. Whelan±, Ting Liu#, An-Chi Wei#, Genaro Ramirez-Correa#, Mark E. McComb±, Catherine E. Costello±, Brian O’Rourke#, Anne Murphy#, Gerald W. Hart†*

†Department of Biological Chemistry, The Johns Hopkins University School of Medicine, Baltimore, MD 21205. ± Department of Biochemistry, Boston University School of Medicine, Boston, MA 02118. #Division of Cardiology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205.

*To whom correspondence should be addressed: Gerald W. Hart, Department of Biological Chemistry, The Johns Hopkins University School of Medicine, Wood Basic Science Building, Rm 515, 725 North Wolfe Street, Baltimore, MD 21205–2185, USA. Phone: 410-6145993; Fax: 410-614-8804; E-mail: [email protected].

1 ACS Paragon Plus Environment


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 2 of 42

ABSTRACT O-linked β-N-acetylglucosamine (O-GlcNAc), a post-translational modification on serine and threonine residues of many proteins, plays crucial regulatory roles in diverse biological events. As a nutrient sensor, O-GlcNAc modification (O-GlcNAcylation) on nuclear and cytoplasmic proteins underlies the pathology of diabetic complications, including cardiomyopathy. However, mitochondrial O-GlcNAcylation, especially in response to chronic hyperglycemia in diabetes, has been poorly explored. We performed a comparative O-GlcNAc profiling of mitochondria from control and streptozotocin

(STZ)-induced

diabetic

rat

hearts,

by

using

an

improved

β-

elimination/Michael addition with isotopic DTT reagents (BEMAD) followed by tandem mass spectrometric analysis. In total, 86 mitochondrial proteins, involved in diverse pathways, are O-GlcNAcylated. Among them, many proteins have site-specific alterations in O-GlcNAcylation in response to diabetes, suggesting that protein OGlcNAcylation is a novel layer of regulation mediating adaptive changes in mitochondrial metabolism during the progression of diabetic cardiomyopathy.

KEY WORDS: Mitochondria, O-GlcNAcylation, O-GlcNAcome, mass spectrometry, proteomics, pyruvate dehydrogenase, diabetic cardiomyopathy


Page 3 of 42

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


INTRODUCTION Since its discovery over 30 years ago,1,2 the cycling of O-linked β-Nacetylglucosamine (O-GlcNAc) on serine and threonine residues of proteins (OGlcNAcylation) has been shown to play crucial roles in diverse biological processes. The highly dynamic O-GlcNAc modification (O-GlcNAcylation) is regulated by two enzymes: O-GlcNAc transferase (OGT) and O-GlcNAcase, which add and remove the O-GlcNAc moiety, respectively. As a major nutrient sensor, protein O-GlcNAcylation, on myriad proteins, underlies the progression of several metabolic diseases, including diabetes and its complications.3,4 Of note, dysregulated O-GlcNAcylation of proteins is a key factor in the etiology of cardiomyopathy.5-9 Mitochondria are at the center stage of regulating cellular metabolism, and mitochondrial dysfunction underlies the progression of cardiovascular disease.10 Changes in protein abundance as well as in post-translational modifications on mitochondrial proteins have been revealed as critical to altered mitochondrial function.1113

However, few studies have been focused on protein O-GlcNAcylation in mitochondria

especially in functional cardiac mitochondria, although a number of techniques have been developed for probing protein O-GlcNAcylation in cardiovascular and other biological settings.14-23 One reason is that mitochondria used to be regarded as an organelle with few O-GlcNAcylated proteins.2,24 Accumulating evidence in recent years shows that protein O-GlcNAcylation does exist in mitochondria.25-27 An overall increased mitochondrial O-GlcNAcylation in neonatal cardiomyocytes exposed to high glucose was observed.25 The very recent identification of mitochondria O-GlcNAc cycling



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

components (i.e., OGT, O-GlcNAcase and a UDP-GlcNAc transporter), the altered enzymatic activity of mitochondrial OGT and O-GlcNAcase, and the mislocalization of OGT, suggest that mitochondrial O-GlcNAcylation plays a role in the progression of diabetic cardiomyopathy.26 On the other hand, rats acutely treated with Thiamet G, a specific inhibitor of O-GlcNAcase, show an overall increased O-GlcNAcylation on mitochondrial proteins, concomitant with enhanced mitochondrial bioenergetics.27 Thus, it is fundamentally important to determine how the mitochondrial O-GlcNAcome responds to a chronic disease, such as diabetes, and how the pattern of OGlcNAcylation may differ from changes after acute treatment. Herein, by coupling isotopic labeling and refined O-GlcNAc enrichment with tandem mass spectrometry techniques, we performed global profiling of O-GlcNAcylation in functional mitochondria from normal or STZ-induced diabetic hearts. We found that the cardiac mitochondrial proteome and O-GlcNAcome were substantially different in the two groups. Of note, a number of metabolic enzymes show altered protein abundance, as well as site-specific O-GlcNAcylation. Our results suggest that, mitochondrial protein O-GlcNAcylation could serve as a critical factor in the initiation and progression of diabetic cardiomyopathy.

EXPERIMENTAL PROCEDURES Experimental animals. Male Sprague-Dawley rats (8-10 weeks) were randomly split into two groups. Control rats received an injection of vehicle buffer. Diabetic rats were treated as described previously.28 Briefly, rats were intraperitoneally injected with a single dose of 75 mg/kg Streptozocin (Sigma). Rats with high blood glucose level (>600


Page 4 of 42

Page 5 of 42

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


mg/dL) were housed for 4 weeks and sacrificed by decapitation. All animal experiments were approved by the Institutional Animal Care and Use Committee of the Johns Hopkins University. Mitochondria isolation. Mitochondria were isolated by differential centrifugation,29 with modifications to obtain highly purified mitochondrial pellets using Percoll-gradient ultracentrifugation. In brief, rat hearts were homogenized in ice-cold Isolation Buffer [75 mM sucrose, 225 mM mannitol, 1 mM EGTA, pH 7.4, supplemented with 1x Protease Inhibitor Cocktail 1 (Roche) and 2 µM O-(2-Acetamido-2-deoxy-D-gluco-pyranosylidene) amino N-phenyl carbamate (Sigma) using a Potter-Elvehjem glass homogenizer. Then fatty acid-free BSA (final conc.: 0.2%) was immediately added, with the resulting homogenates centrifuged for 5 min at 500 x g. The resulting supernatants were centrifuged for 10 min at 7,700 x g, with pellets washed twice thereafter by centrifugation at 7,700 x g for 5 min each. The isolated mitochondria were used for functional assays. For the purity assay and proteomics experiments, mitochondrial pellets were resuspended in isolation buffer A and layered onto a discontinuous gradient consisting of (from top to bottom) 6% Percoll, 17% and 35% Histodenz (Sigma), each made up in sucrose buffer. After centrifugation with a Ti41 rotor (Beckman) at 17,500 rpm for 30 minutes, the layer at the 17%/35% interface was collected and diluted with Isolation Buffer and centrifuged at 10,000 x g to remove Histodenz. The protein concentration was then determined by using the BCA Assay kit (Thermo Fisher Scientific). Mitochondrial functional assessment. Mitochondrial oxygen consumption rates were determined with a 96-well extracellular flux analyzer (XF96; Seahorse Bioscience), as



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

described previously.30 In brief, 5-15 µg of isolated mitochondria in assay buffer (137 mM KCl, 2 mM KH2PO4, 0.5 mM EGTA, 2.5 mM MgCl2, and 20 mM HEPES at pH 7.2, and 0.2% fatty acid free BSA) were transferred into a 96-well XF96 plate precoated with polyethylenimine. The plate was spun at 3,000 x g for 7 min at 4 °C, and then incubated at 37°C for 20 min. The respiration was measured with the flux analyzer in the presence of 5 mM glutamate/malate [G/M] or 5 mM succinate without 1 mM ADP (State 4) or with 1 mM ADP (State 3). Mitochondrial Ca2+ uptake capacity was assayed as reported previously,31 with mitochondria (0.5 mg) suspended in a potassium-based buffer (i.e., 137 mM KCl, 2 mM KH2PO4, 20 µM EGTA, 20 mM HEPES, and 5 mM glutamate/malate at pH 7.15). Calcium green-5N fluorescence was recorded by a fluorometer (PTI Quantamaster) at 37°C (excitation: 505 nm; emission: 535 nm), and CaCl2 was added sequentially (15 µM free Ca2+ for the first addition and 25 µM for subsequent additions). NADH fluorescence was recorded either in the presence of 5 mM G/M or 5 mM succinate (excitation: 350 nm; emission: 450 nm). Tetramethylrhodamine methyl ester was used for ratiometric measurement of mitochondrial membrane potential (∆Ψm) by monitoring emission at 590 nm with excitations of 546 nm and 573 nm, as described previously.31 Mitochondrial sample purity assay. The purity of the rat heart mitochondrial preparation was assessed according to Foster et al.29. Briefly, equal amounts of proteins from the post-nuclear supernatant/cytosolic fraction and Percoll-gradient purified mitochondria were supplemented with 4x Laemmli buffer (Bio-Rad). After loading onto the top of a 10% SDS-PAGE gel (Bio-Rad) overlaid with 0.5% agarose, proteins were separated at 110 v for 1.5 h. Proteins in gels were electrotransferred to a


Page 6 of 42

Page 7 of 42

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


PVDF membrane. The PVDF membrane was blocked using 5% BSA in 1x TBST [i.e., 100 mM Tris-HCl, 0.9% (w/v) NaCl, 0.1% (v/v) Tween-20)], incubated with antibodies to SDHA (Invitrogen), NDUFS3 (Invitrogen), ATP5B (Invitrogen), alpha-tubulin (Sigma), or GAPDH (Sigma). After overnight agitation, the membrane was then incubated with specific secondary HRP-conjugated antibodies (Santa Cruz) under gentle agitation for 1 h. Chemiluminescence was performed under manufacturer protocols, by using ECL films (GE Healthcare). Blots were washed 5 times for 10 min in 1x TBST between blocking, antibody incubations and chemiluminescence detection. Two-dimensional gel (IEF/SDS-PAGE) analysis of mitochondrial samples. The highly purified mitochondrial pellets were lysed in buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Triton X-100, 1 mM NaF, 1 mM β-glycerophosphate, 2 µM O-(2Acetamido-2-deoxy-D-glucopyranosylidene)

amino

N-phenyl

carbamate,

and

1x

Protease Inhibitor Cocktail 1 (Sigma). After being sonicated for 2x 10 s, the suspension was spun down at 12,000 x g for 15 min. The supernatant was collected and the mitochondrial proteins were extracted by acetone precipitation. The precipitated proteins were vacuum dried and then dissolved in Rehydration Buffer [8 M urea, 2% CHAPS, 50 mM DTT, 0.2% Ampholytes (Bio-Rad)]. After being immersed in the protein suspensions overnight, Readystrip IPG strips (Bio-Rad) were transferred onto an Ettan IPGphor3 IEF system (GE Healthcare) for IEF separation following the manufacturer instructions. The strips were incubated sequentially with DTT-Equilibration Buffer (containing 50 mM Tris-HCl, pH 8.8, 6 M urea, 30% glycerol, 2% SDS, 0.002% Bromophenol Blue, and 65 mM DTT) and Iodoacetamide-Equilibration Buffer (containing 50 mM Tris-HCl, pH 8.8, 6 M urea, 30% glycerol, 2% SDS, 0.002%



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Bromophenol Blue, and 135 mM iodoacetamide) for 30 min. The strips were then loaded onto 10-20% Criterion Gels (Bio-Rad) for a 2nd dimensional SDS-PAGE separation. Proteins in gels were electrotransferred to a PVDF membrane and probed with self-purified CTD110.6 and RL2 antibody [using mouse IgM-HRP and mouse HRPconjugated IgG as secondary antibody (Santa Cruz) respectively], with the same procedures mentioned above. Primary antibodies incubated with 1 M GlcNAc for at least 2 h at 4 °C before blotting were used for competitive assay. Mitochondrial sample preparation and TMT labeling. Acetone precipitated mitochondrial proteins from 4 control rats and 4 diabetic rats (9 mg of each) were vacuum dried and dissolved in 8 M urea supplemented with 50 mM triethylammonium bicarbonate (pH 8), with the protein concentration determined by the BCA assay. An equal amount of proteins (9 mg of each) was reduced with 10 mM DTT, alkylated with 30 mM iodoacetamide, and in-solution digested overnight by trypsin. The resulting peptides were then treated with calf alkaline phosphatase (New England Biolab) and PNGase F (New England Biolab) for another 12 h. The peptides were desalted with C18 Sep-Pak columns (Waters) and dried with lyophilization. A small portion (1%) of the peptides was isotopically labeled with a 6-plex TMT kit (Thermo Fisher Scientific) according to the manufacturer’s protocol. The labeled peptides were pooled, fractionated by a basic pH reversed-phase liquid chromatography (bRPLC, as described in a previous report32) into 12 fractions, dried down and then analyzed by LC-MS/MS for protein quantification. O-GlcNAc peptide enrichment. The remaining peptides (99%) from control and diabetic cardiac mitochondria were subjected to beta-elimination and Michael-addition


Page 8 of 42

Page 9 of 42

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


with d0- and d6-DTT (BEMAD), respectively, with slight modifications.33-35 Briefly, peptides were dissolved in BEMAD buffer [1.5% (v/v) triethylamine, 20 mM d0-DTT or d6-DTT, 20% (v/v) ethanol, pH 12.5 by NaOH]. After incubation at 50°C for 4 h, the reaction was neutralized with trifluoroacetic acid. The DTT-substituted peptides were pooled and incubated with thiol-sepharose resin (Sigma) in degassed PBS containing 1 mM EDTA (PBS/EDTA, pH 7.4) for 4 h. The resin was extensively washed with PBS/EDTA and 40% acetonitrile, then DTT-containing peptides were released by PBS/EDTA containing 20 mM free DTT. Eluted peptides were desalted with C18 spin columns (Nest Group) for LC/MS/MS analysis. LC-MS/MS analysis. An LTQ-Orbitrap Velos (Thermo Fisher Scientific) attached to Waters UPLC chromatography system was used for tandem mass spectrometry analysis of the peptides. Loaded peptides were trapped on a 2 cm trap column (YMC gel ODS-A S-10 µm), fractionated with a 75 µm x 15 cm column [Magic C18 AQ, 5 µm, 100 Å (Michrom Bioresources)], and then electrosprayed through a 15-µm emitter (New Objective). A reversed-phase solvent gradient, which consisted of solvent A (0.1% formic acid) with increasing levels of solvent B (0.1% formic acid, 90% acetonitrile) over a period of 90 minutes, was used for peptide separation. The LTQ Orbitrap Velos was set at 2.0 kV spray voltage, full MS survey scan range m/z 350-1800 m/z, datadependent HCD MS/MS analysis of top 8 precursors with minimum signal of 2,000, 30s dynamic exclusion limit, isolation width of 1.2, and normalized collision energy of 40. The precursor and fragment ions were analyzed at resolutions 30,000 and 15,000, respectively.



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 10 of 42

Database search and data interpretation. Tandem mass spectra were processed by Proteome Discoverer (v1.4 Thermo Fisher Scientific) using three nodes: common, Xtract (spectra were extracted, charge state deconvoluted, and deisotoped using Xtract option), and MS2 Processor. MS/MS spectra from three nodes were then analyzed with Mascot v.2.2.2 (MatrixScience) using the RefSeq rat database (2012), with concatenated decoy database, specifying Rattus as species, trypsin/P as enzyme, missed cleavage 2, precursor mass tolerance 15 ppm, and fragment mass tolerance 0.03 Da. For TMT labeled samples, carboamidomethylation (Cys) and TMT (Lys and Nterm) were set as fixed modification and deamidation (Asn/Gln) was set as variable modifications. For the enriched DTT peptides, oxidation (Met), d0-/d6 DTT (Ser/Thr/Cys), and carboamidomethylation (Cys), and deamidation (Asn/Gln) were set as variable modifications. The false discovery rate was set to 0.01 for peptides and proteins. Areas were calculated by Proteome Discoverer 2.0 at 3 ppm mass accuracy. All MS/MS spectra identifying proteins, peptides, or sites were manually inspected for accuracy

with

reference

to

Protein

Prospector

(http://prospector.

ucsf.edu/prospector/mshome.htm), according to previously described rules.36 Bioinformatics. Mitochondrial localization annotations of proteins were assigned from at least two prediction software programs including Target P 1.1, Mitoprot, and Predator. 37-39

We also compared our results with a previous dataset on the rat heart

mitochondrial proteome to confirm its subcellular location. WebLogo40 was used to analyze the frequency of amino acids adjacent to the O-GlcNAcylation sites in the peptide sequence. Datasets about the changes of protein abundance between control and diabetic hearts were analyzed by Ingenuity Pathway Analysis (IPA; QIAGEN) for


Page 11 of 42

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


putative upstream regulators and protein interactions. Immunoblotting of PDH/PDC. The immunoprecipitation of mitochondrial proteins was performed with a commercially available kit (AbCam). Briefly, mitochondrial pellets from control and diabetic hearts were resuspended in 1x PBS buffer supplemented with 1x detergent (AbCam) and 1x Protease Inhibitor Cocktail 1. After being incubated on ice for 30 min, the suspension was spun down at 12,000 x g for 15 min. The supernatant was collected, with protein concentration determined by BCA assay. An equal amount of proteins was incubated with 100 µL antibody-conjugated resin toward PDH/PDC, with a final volume of 1 mL in PBS. After overnight rotation, the resin was washed 5 times with 1x Wash Buffer (AbCam). For the CpNag J treatment, immunoprecipitates from control mitochondria were incubated with CpNag J in 20 mM HEPES (pH 7.4) with a protein/CpNag J = 10/1 (w/w) at 37°C for 2 h. The vehicle buffer [20 mM HEPES (pH 7.4)] was used for samples without CpNag J treatment. The immunocaptured PDH/PDC was released by using the Glycine buffer (AbCam) and then supplemented with 4x Laemmli buffer, according to manufacturer instructions. Samples were loaded onto 10% Criterion Gels (Bio-Rad) for SDS-PAGE separation. Proteins in the gels were electrotransferred to a PVDF membrane and probed with RL2 antibody or PDHA1 antibody (AbCam), with the same procedures mentioned above.

RESULTS Functional assessment of mitochondria from control and diabetic hearts. Aberrant mitochondrial metabolism plays a fundamental role in the pathogenesis of diabetic cardiomyopathy. Herein we initially determined the functionality of cardiac mitochondria



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 12 of 42

from control and streptozotocin (STZ)-induced diabetic rats. Compared to controls, mitochondria from diabetic hearts show markedly depressed maximum respiratory rates under the oxidative phosphorylation (OXPHOS) status (State 3) by using a 96-well extracellular flux analyzer (Figure 1A-B). Our observation is in line with the previous reports in which substantially decreased respiration was observed in isolated mitochondria from STZ-treated mice by oxygraph chambers41 and in homogenates of STZ-treated rat hearts42. Moreover, diabetic mitochondria took a longer time to phosphorylate a limited amount of ADP, as evidenced by slower repolarization of ∆Ψm after ADP addition (Figure 1C-D), suggesting a decreased capacity for ATP synthesis. In addition, maximum ∆Ψm was lower in mitochondria from diabetic hearts (Figure 1CD), even though maximal mitochondrial NADH levels were similar in either glutamate/malate or succinate with inhibition of cytochrome oxidase (after the addition of KCN; Figure S1A-B). These results suggest that mitochondrial bioenergetics is significantly impaired in diabetic hearts. Although kinetically impaired, the integrity of isolated mitochondria was largely preserved, as can be judged from the lack of a significant difference in respiratory control ratio (RCR) for mitochondria between groups (Figure 1E). In addition, we observed that mitochondrial Ca2+ uptake capacity before the opening of the mitochondrial permeability transition pore (mPTP) was lower in mitochondrial from diabetic hearts (Figure 1F), which is consistent with a previous report.43 Alterations in Mitochondrial Protein Abundance in Diabetic Heart. By using Percollgradient ultracentrifugation, highly purified mitochondria were obtained, for which the purity characterization is shown in Figure S2. To define the global changes in protein


Page 13 of 42

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


abundance in functional cardiac mitochondria between control and diabetic rats, proteomic profiling was performed (as shown in Figure S3). By combining the isotopic Tandem Mass Tag™ (TMT, Thermo Fisher Scientific) labeling and tandem mass spectrometry, 352 mitochondrial proteins were identified and quantified (with a false positive discovery rate 7-fold for PDK4), indicating that mitochondrial glucose oxidation in the diabetic heart might be substantially impaired. However, the abundances of almost all proteins involved in fatty acid transport and oxidation were increased (Figure 2; Table S1), suggesting that diabetic hearts might rely more heavily on fatty acid as their fuel. Indeed, these results support the notion that there is decreased capacity for glycolysis and for pyruvate decarboxylation but concomitant elevation of fatty acid oxidation (FAO) in cardiac mitochondria in diabetes.44 And the metabolic remodeling from glucose oxidation to fatty acid oxidation in heart has been regarded to be an early event initiating progression of diabetic cardiomyopathy.44 In contrast, the abundance of proteins within the OXPHOS system seems to change bi-directionally (Table S1). Notably, 14 proteins in complex I showed strikingly



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 14 of 42

decreased abundance. Considering that complex I is the first site of proton pump coupled to NADH oxidation and transports electrons to complex III, the down-regulation of complex I components could account for the diminished maximal oxygen consumption rate and slower ADP phosphorylation in G/M. Moreover, it could contribute to increased reactive oxygen species production in diabetic cardiac mitochondria. Although 14 proteins in complex IV showed increased abundance, a decreased enzymatic activity was observed in diabetic hearts26, which might lead to further increased oxidative stress in diabetes. Since our discussion based mainly on the measured protein level changes, we cannot rule out the possibility that other factors (e.g., post-translational modifications), together with the altered protein abundance, contribute to the defective mitochondrial bioenergetics in diabetic hearts. IPA analysis was performed to explore the potential upstream regulators for the altered abundance of mitochondrial proteins in control and diabetic hearts. Very interestingly, the signaling network mediated by several transcriptional factors (including peroxisome proliferator-activated receptor α (PPARA), peroxisome proliferator-activated receptor δ (PPARD), and estrogen-related receptor alpha (ESRRA)) are shown to be key contributors to the elevated abundance of components in fatty acid utilization and decreased abundance in other mitochondrial processes (Figure S4). Indeed, in accordance with the previously described regulatory roles of these proteins in diabetic hearts or closely related conditions45-47, these results suggest that transcriptional regulation of metabolic pathways plays an important role in mitochondrial dysfunction in chronic diabetic hearts. It is noteworthy that we did not observe obvious TMT ratio compression in this study,


Page 15 of 42

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


probably due to the relatively less complex organelle proteome (i.e., mitochondrial lysate) and the extensive fractionation of the peptide pool.48 Moreover, the gel-free approach we used is especially appealing compared to the gel-based protein profiling for diabetic mitochondria described in previous studies.49,50 Since mitochondria are rich in basic and hydrophobic proteins, gel-based proteomics is particularly unsuitable for the identification of mitochondrial proteins.51 Moreover, protein quantification from certain gel spots “identified” as specific proteins may include contributions from other unresolved proteins, and changes in spot density may not reliably reflect actual changes in protein expression since post-translational modifications may alter migration patterns. Indeed, numerous hydrophobic proteins including MPC1, VDAC1/2, and SLC25A4, have been positively identified and quantified in our study. Of note, some of the mitochondrial DNA encoded multi-pass membrane proteins including MT-ND2 and MTND5, have been successfully identified and quantified as well. The increased MT-ND2 and decreased MT-ND5, in combination with the altered abundance of mitochondrial biosynthetic machinery proteins (Table S1), adds further evidence to the bi-directional changes of protein abundance contributing to the mitochondrial dysfunction in chronic diabetes. Extensive O-GlcNAcylation of Mitochondrial Proteins. To gain a preliminary view of mitochondrial protein O-GlcNAcylation, we performed two-dimensional gel separation (i.e., IEF and SDS-PAGE) of the mitochondrial proteins. A number of spots were seen after immunoblotting with CTD 110.6, a commonly used O-GlcNAc-specific antibody (Figure 3A-3B). Surprisingly, while the O-GlcNAcylation on some proteins was increased, it was found to be strikingly decreased on others. These observations have



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 16 of 42

been further confirmed by using another pan-specific O-GlcNAc antibody RL2, although a slightly different O-GlcNAc recognition pattern was exhibited (Figure S5). Instead of using the 2-D gel-based method for identification of O-GlcNAcylated proteins, we adopted a gel-free approach to determine the molecular identity of the OGlcNAc proteins in cardiac mitochondria. Specifically, a large-scale O-GlcNAcomic profiling was conducted, by combining a refined β-elimination/Michael addition with light/heavy DTT (BEMAD) approach and tandem mass spectrometry (Figure 3)33-35. In total, 86 mitochondrial proteins (with 167 sites) were found to be O-GlcNAcylated from control and diabetic hearts (Figure 4), with detailed information of modified peptides shown in Table S2 and Figure S6. Among them, 56 proteins (~65%) have ≥ 2 O-GlcNAc sites. It is noteworthy that multiple enzymes in major metabolic pathways (including the TCA cycle, and fatty acid oxidation) are O-GlcNAc modified. Intriguingly, PDHA1, the α subunit of PDH in PDC, is also O-GlcNAcylated, with 2 sites mapped. In addition, although the sequence analysis of the overall pattern of O-GlcNAcylation sites, as expected, does not show an O-GlcNAcylation consensus motif, the data do indicate a preference for the presence of hydrophobic amino acids prior to the OGlcNAc site and polar amino acids following it (Figure S7). Differential O-GlcNAcylation of Mitochondrial Proteins in Control and Diabetic Hearts. The site-specific O-GlcNAc changes in diabetic hearts were determined by the corresponding peak area of peptides containing either light or heavy isotopes. Considering that the abundance of many proteins is markedly changed between control and diabetic hearts, the site-specific O-GlcNAc changes were normalized to the abundance of corresponding proteins [i.e., O-GlcNAc relative site occupancy ratio


Page 17 of 42

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


(ROR)], by using the following equation: ROR(Diabetes/Control) = [O-GlcNAc]Diabetes/[Protein]Diabetes [O-GlcNAc]Control/[Protein]Control To our surprise, although 45 sites (~26%) showed increased O-GlcNAcylation by ≥1.2fold, 68 sites (~40%) showed decreased O-GlcNAc level by 20% in diabetic mitochondria (Table S3), suggesting dynamic O-GlcNAcylation of mitochondrial proteins. Interestingly, a relatively stable site occupancy (i.e., ROR = 1) is observed for some proteins (e.g., ACAA2 and CKMT2), since the altered O-GlcNAc level (e.g., S357 of ACAA2 and S51 of CKMT2) is proportional to fold-chance of the protein abundance of proteins in diabetic hearts (Table S3). This result suggest that the O-GlcNAc level on certain sites might be directly resulting from the altered abundance of some proteins. Moreover, it seems that the ROR values of a number of other individual O-GlcNAc sites are regulated in a more complicated way independent of protein abundance, as exemplified by S231 of ATP5B, S144 of NDUFB5, and S242 of NNT (Figure 5A). Of note, the bi-directional change also occurs on individual proteins with ≥ 2 sites (e.g., DLAT, CTP1B, HADHA, and HADHB; Figure 5A-B). Even more intriguingly, a number of proteins even showed decreased RORs of all their sites identified, including PDHA1 and SDHA (Figure 5A; Table 3). Although overall increases in O-GlcNAcylation in mitochondria from high-glucosetreated cardiomyocytes25 or STZ-induced diabetic hearts26 have been observed previously, the O-GlcNAcomic profiling data presented here suggest that many cardiac mitochondrial proteins are actually differentially O-GlcNAcylated between control and diabetes and that the bi-directional site-specific O-GlcNAcylation changes are partially



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 18 of 42

the result of the protein abundance changes. Mislocalization of the O-GlcNAc transferase within cardiac mitochondria in diabetic hearts could be another contributor to

this

phenomenon.26

Since

the

cross-talk

between

O-GlcNAcylation

and

phosphorylation has been detected on multiple nuclear and cytoplasmic proteins52,53, changes in mitochondrial phosphoproteomic pattern might also affect the site-specific O-GlcNAc levels within mitochondria. The results of an investigation into this point will provide deeper insight into the bi-directional O-GlcNAc changes in diabetic mitochondrial proteins (Junfeng Ma, et al. Manuscript in preparation). The unanticipated complexity of the regulation on the occupancy level of specific O-GlcNAc sites implies that differential O-GlcNAcylation status may site-specifically alter the functions of individual mitochondrial proteins. Validation of O-GlcNAcylation of Pyruvate Dehydrogenase (PDH). PDHA1, the α subunit of PDH, is the major known regulatory factor that governs the conversion of pyruvate to Acetyl-CoA.54 PDH was immunoprecipitated from rat cardiac mitochondria lysate and probed with RL2 for PDHA1. Indeed, PDHA1 is O-GlcNAcylated even in control hearts (Figure 6). Moreover, a ~20% decreased O-GlcNAcylation was observed in diabetic cardiac mitochondria (Figure 6). To further confirm the O-GlcNAc status of PDHA1, immunoprecipitated PDH was treated by CpNag J (Clostridium perfringens Nag J), a recombinant homolog of human O-GlcNAcase.55 As expected, CpNag J treatment potently removed O-GlcNAc from PDHA1 (Figure 6). Taken together, these results suggest that PDHA1 is O-GlcNAcylated, and its O-GlcNAcylation might be directly involved in the regulation of PDH and thus the metabolic dysregulation in the development of diabetic cardiomyopathy.


Page 19 of 42

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


DISCUSSION Studies on nuclear and cytoplasmic O-GlcNAcylation have suggested that aberrant protein O-GlcNAcylation is an important contributor to the diverse adverse effects on the diabetic heart. The recent identification of mitochondrial O-GlcNAc cycling components (i.e., OGT, O-GlcNAcase and a UDP-GlcNAc transporter), the altered enzymatic activity of mOGT and O-GlcNAcase, and the mislocalization of OGT suggest that mitochondrial O-GlcNAcylation can be an underlying factor in the progression of diabetic cardiomyopathy. 26 In the present study, we systematically investigated the bioenergetics of mitochondria isolated from control and streptozotocin (STZ)-induced diabetic hearts. In comparison to controls, the diabetic cardiac mitochondria show diminished oxygen consumption rates, slower ADP phosphorylation rates, and impaired recovery of ∆Ψm (especially in steady-state respiration status), suggesting inefficient ATP production. Providing that sustained heart function is completely dependent on mitochondriallyderived ATP to fuel contraction, the reduced metabolic efficiency should have detrimental effects on cardiac function. Moreover, the lower Ca2+ activation threshold for mPTP opening might further exacerbate the progressive decline of cardiac function in diabetes. The cardiac proteomes of the functionally active mitochondria were stable isotopelabeled and analyzed by advanced mass spectrometry methods, yielding a pattern of protein abundance in diabetes that is different from controls. The results from our comprehensive profiling of the mitochondrial proteome provide extensive evidence that



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 20 of 42

there is metabolic remodeling in diabetic hearts, from glucose utilization to fatty acid oxidation, and this precedes the onset of cardiac dysfunction. Moreover, the bidirectional changes in the abundances of other proteins (including OXPHOS proteins) afford detailed insights into the impaired bioenergetics and accompanying mitochondrial dysfunction in diabetic hearts. Mitochondrial O-GlcNAcomics, in control and diabetic hearts, was enabled through the use of a refined BEMAD approach. We find that many cardiac mitochondrial proteins are O-GlcNAcylated. The O-GlcNAcylated proteins are involved in multiple mitochondrial pathways, including pyruvate decarboxylation, fatty acid oxidation (FAO), TCA cycle, oxidative phosphorylation, mitochondrial protein import machinery, and others. Since many of these processes are proposed to be correlated with insulin resistance, we hypothesize that O-GlcNAcylation of mitochondrial proteins is likely related to insulin resistance in chronic diabetes. Moreover, unexpectedly, O-GlcNAc site occupancy on mitochondrial proteins is subject to bi-directional changes (i.e., either upregulated or down-regulated) between the control and diabetic hearts, and OGlcNAcylation at certain sites of individual proteins can even be reduced in diabetic hearts. This seemingly paradoxical observation casts doubt on the notion that protein OGlcNAcylation could be uniformly elevated with the induction of hyperglycemia. Several possible mechanisms might explain this finding: 1) O-GlcNAc transferase is abnormally localized in the mitochondria from diabetic hearts, perhaps causing its inability to OGlcNAcylate certain sites on proteins; 2) the aberrant mitochondrial O-GlcNAc cycling in chronic diabetes might substantially affect the O-GlcNAcylation of its targets; 3) OGlcNAcylation modifies many kinases and the modification might activate certain


Page 21 of 42

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


mitochondrial kinases, thus decreasing O-GlcNAcylation due to competition;3,52,53 4) akin to protein phosphorylation, different O-GlcNAc sites of individual proteins may respond differentially to certain physiological or pathological stimuli, and this sitespecific O-GlcNAcylation might consign specific roles to proteins in contributing to mitochondrial (dys)function. Therefore, it is very likely that the dynamic O-GlcNAc cycling of individual mitochondrial proteins is more complicated than previously expected. By using immunoprecipitation and Western blotting with pan-specific antibody, we validated the O-GlcNAc status of PDHA1, a key subunit of the enzyme PDH which regulates the conversion of pyruvate to Acetyl-CoA. Indeed, PDHA1 is O-GlcNAcylated in control hearts, which was then confirmed by the treatment with CpNag J, a recombinant homolog of human O-GlcNAcase. The potent removal of O-GlcNAc on PDHA1 by CpNag J also suggests that mitochondrial proteins could be potential targets for O-GlcNAcase. In comparison to control hearts, the overall O-GlcNAcylation level of PDHA1 was ~20% decreased in diabetic hearts. This change could be due to the crosstalk between O-GlcNAcylation

and

phosphorylation,

since

not

only

the

overall

increased

phosphorylation54 but also site-specifically increased phosphorylation on PDH have been observed in diabetic hearts (Junfeng Ma, et al. Manuscript in preparation). Considering that the increased phosphorylation, together with other factors,56 decreases the activity of PDH/PDC and thus diminishes glucose utilization, we reason that OGlcNAcylation should serve a regulatory role in cardiac metabolism, contributing to the progression of diabetic cardiomyopathy. The determination of the O-GlcNAc



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 22 of 42

stoichiometry of PDHA1 is underway for detailed delineation of its functional importance. As the most abundant post-translational modification, glycosylation has been found on numerous proteins.57 Although a few mitochondrial proteins were regarded to be Nglycosylated,58-60 whether there is a bona fide N-glycosylation synthetic machinery is still not widely accepted, and the characterization of the corresponding glycosyltransferases and hydrolases is incomplete. Herein, we show that O-GlcNAcylation exists on many mitochondrial proteins, suggesting that O-GlcNAcylation is probably the major glycosylated form on proteins within mitochondria. Moreover, the O-GlcNAcyation mediated by the O-GlcNAc cycling components (all of which are present in mitochondria)26 is a dynamic process, exerting important regulatory roles in mitochondria.

ASSOCIATED CONTENT The Supporting Information is available free of charge on the ACS Publications website at DOI:.

Figure S1: The relative NADH level (State 3 / State 4) of isolated mitochondria from control and diabetic rats with the presence of glutamate/malate (G/M; A) and succinate (Succ.; B). Figure S2: Purity of isolated mitochondria from control and diabetic rats. Figure S3: Schematic of the cardiac mitochondria O-GlcNAcomic profiling for control and diabetic rats. Figure S4: The network of pathways that lead to altered abundance of mitochondrial proteins by using ingenuity pathway analysis. Figure S5: RL2 immunoblotting of cardiac mitochondria from control and diabetic rats. Figure S6: Mass


Page 23 of 42

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


spectra of O-GlcNAcylated peptides of cardiac mitochondria proteins. Figure S7: The sequence motif of mitochondrial O-GlcNAcylation. (PDF)

Table S1: Changes of mitochondrial protein abundance between control and diabetic hearts. Table S2: he identified O-GlcNAc peptides of mitochondrial proteins from control and diabetic hearts. Table S3: Changes in O-GlcNAc ROR in mitochondrial proteins between control and diabetic hearts. (XLSX)

ACKNOWLEDGEMENTS The kind gift of CpNag J from Dr. Daan van Aalten lab (University of Dundee, Dundee, UK) is acknowledged. We thank Dr. Jennifer Van Eyk lab, Dr. Hui Zhang lab, Dr. Akhilesh Pandey lab, and the current and previous Hart lab members for their great help and insightful discussions. This work was supported by, P01HL107153, NIH N01-HV00240, and R01DK61671 to GWH, NHLBI Contract HHSN268201000031C and NIH grant P41 GM104603 to CEC and MEM, and HHSN268201000032C to AMM, GWH, and BOR. Dr. Hart receives a share of royalties received by the university on sales of the CTD 110.6 antibody, which is managed by the Johns Hopkins University.

REFERENCES 1. Torres, C.R.; Hart, G.W. Topography and polypeptide distribution of terminal Nacetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc. J Biol Chem. 1984, 259, 3308-3317.



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 24 of 42

2. Holt, G.D.; Hart, G.W. The subcellular distribution of terminal N-acetylglucosamine moieties: Localization of a novel protein-saccharide linkage, O-linked GlcNAc. J Biol Chem. 1986, 261, 8049-8057. 3. Hardivillé, S.; Hart, G.W. Nutrient regulation of signaling, transcription, and cell physiology by O-GlcNAcylation. Cell Metab. 2014, 20, 208-213. 4. Ma, J.; Hart, G. W. Protein O-GlcNAcylation in diabetes and diabetic complications. Expert Rev Proteomics 2013, 10, 365-380. 5. Wang, Z. V.; Deng, Y.; Gao, N.; Pedrozo, Z.; Li, D. L.; Morales, C. R.; Criollo, A.; Luo, X.; Tan, W.; Jiang, N.; Lehrman, M. A.; Rothermel, B. A.; Lee, A. H.; Lavandero, S.; Mammen, P. P.; Ferdous, A.; Gillette, T. G.; Scherer, P. E.; Hill, J. A. Spliced X-box binding protein 1 couples the unfolded protein response to hexosamine biosynthetic pathway. Cell 2014, 156, 11791192. 6. Heath, J. M.; Sun, Y.; Yuan, K.; Bradley, W.E.; Litovsky, S.; Dell'Italia, L. J.; Chatham, J. C.; Wu, H.; Chen, Y. Activation of AKT by O-linked N-acetylglucosamine induces vascular calcification in diabetes mellitus. Circ Res 2014, 114, 1094-1102. 7. Ramirez-Correa, G.A., Ma, J., Slawson, C., Zeidan, Q., Lugo-Fagundo, N.S., Xu, M., Shen, X., Gao, W.D., Caceres, V., Chakir, K., DeVine, L., Cole, R.N., Marchionni, L., Paolocci, N., Hart, G.W., Murphy, A.M. Removal of abnormal myofilament O-GlcNAcylation restores Ca2+ sensitivity in diabetic cardiac muscle. Diabetes 2015, 64, 3573-3587. 8. Bennett, C. E.; Johnsen, V. L.; Shearer, J.; Belke, D.D. Exercise training mitigates aberrant cardiac protein O-GlcNAcylation in streptozotocin-induced diabetic mice. Life Sci 2013, 92, 657-663. 9. Erickson, J.R.; Pereira, L.; Wang, L.; Han, G.; Ferguson, A.; Dao, K.; Copeland, R.J.; Despa, F.; Hart, G.W.; Ripplinger, C.M.; Bers, D.M. Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation. Nature 2013, 502, 372-376.


Page 25 of 42

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


10. Nunnari, J.; Suomalainen, A. Mitochondria: in sickness and in health. Cell 2012, 148, 11451159. 11. Zong, N.C.; Li, H.; Li, H.; Lam, M.P.; Jimenez, R.C.; Kim, C.S.; Deng, N.; Kim, A.K.; Cho, J.H.; Zelaya, I.; Liem, D.; Meyer, D.; Odeberg, J.; Fang, C.; Lu, H.J.; Xu, T.; Weiss, J.; Duan, H.; Uhlen, M.; Yates, J.R.; Apweiler, R.; Ge, J.; Hermjakob, H.; Ping, P. Integration of cardiac proteome biology and medicine by a specialized knowledgebase. Circ Res. 2013, 113, 10431053. 12. Del Monte, F.; Agnetti, G. Protein post-translational modifications and misfolding: new concepts in heart failure. Proteomics Clin Appl. 2014, 8, 534-542. 13. Lindsey, M.L.; Mayr, M.; Gomes, A.V.; Delles, C.; Arrell, D.K.; Murphy, A.M.; Lange, R.A.; Costello, C.E.; Jin, Y-F.; Laskowitz, D.T.; Sam, F.; Terzic, A.; Van Eyk, J.; Srinivas, P.R. Transformative impact of proteomics on cardiovascular health and disease: a scientific statement from the American Heart Association. Circulation 2015, 132, 852-872. 14. Vocadlo, D.J., Hang, H.C., Kim, E.J., Hanover, J.A., Bertozzi, C.R. A chemical approach for identifying O-GlcNAc-modified proteins in cells. Proc Natl Acad Sci USA 2003, 100, 91169121. 15. Nandi, A.; Sprung, R.; Barma, D.K.; Zhao, Y.; Kim, S.C.; Falck, J.R.; Zhao, Y. Global identification of O-GlcNAc-modified proteins. Anal. Chem. 2006, 78, 452-458. 16. Clark, P.M.; Dweck, J.F.; Mason, D.E.; Hart, C.R.; Buck, S.B.; Peters, E.C.; Agnew, B.J.; Hsieh-Wilson, L.C. Direct in-gel fluorescence detection and cellular imaging of O-GlcNAcmodified proteins. J Am Chem Soc. 2008, 130, 11576-11577. 17. Chalkley, R.J.; Thalhammer, A.; Schoepfer, R.; Burlingame, A.L. Identification of protein OGlcNAcylation sites using electron transfer dissociation mass spectrometry on native peptides. Proc Natl Acad Sci USA 2009, 106, 8894-8899. 18. Wang, Z.; Udeshi, N.D.; Slawson, C.; Compton, P.D.; Sakabe, K.; Cheung, W.D.; Shabanowitz, J.; Hunt, D.F.; Hart, G.W. Extensive crosstalk between O-GlcNAcylation and



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 26 of 42

phosphorylation regulates cytokinesis. Sci Signal 2010, 3, ra2. 19. Zhao, P.; Viner, R.; Teo, C.F.; Boons, G.J.; Horn, D.; Wells, L. Combining high-energy Ctrap dissociation and electron transfer dissociation for protein O-GlcNAc modification site assignment. J Proteome Res. 2011, 10, 4088-4104. 20. Parker, B.L.; Gupta, P.; Cordwell, S.J.; Larsen, M.R.; Palmisano, G. Purification and identification of O-GlcNAc-modified peptides using phosphate-based alkyne CLICK chemistry in combination with titanium dioxide chromatography and mass spectrometry. J Proteome Res. 2011, 10, 1449-1458. 21. Trinidad, J.C.; Barkan, D.T.; Gulledge, B.F.; Thalhammer, A.; Sali, A.; Schoepfer, R.; Burlingame, A.L. Global identification and characterization of both O-GlcNAcylation and phosphorylation at the murine synapse. Mol Cell Proteomics 2012, 11, 215-229. 22. Hahne, H.; Sobotzki, N.; Tamara, N.; Helm, D.; Borodkin, V.S.; van Aalten, D.M.; Agnew, B.; Kuster, B. Proteome wide purification and identification of O-GlcNAc-modified proteins using click chemistry and mass spectrometry. J Proteome Res. 2013, 12, 927-936. 23. Nagel, A.K.; Schiling, M.; Comte-Walters, S.; Berkaw, M.N.; Ball, L.E. Identification of OGlcNAc-modified osteoblast proteins by electron transfer dissociation tandem mass spectrometry reveals proteins critical for bone formation. Mol Cell Proteomics 2013,12, 945955. 24. Love, D.C.; Kochan, J.; Cathy, R.L.; Shin, S.H.; Hanover, J.A. Mitochondrial and nucleocytoplasmic targeting of O-linked GlcNAc transferase. J Cell Sci. 2003,116, 647-654. 25. Hu, Y.; Suarez, J.; Fricovsky, E.; Wang, H.; Scott, B.T.; Trauger, S.A.; Han, W.; Oyeleye, M.O.; Dillmann, W.H. Increased enzymatic O-GlcNAcylation of mitochondrial proteins impairs mitochondrial function in cardiac myocytes exposed to high glucose. J Biol Chem 2009, 284, 547-555. 26. Banerjee, P.S.; Ma, J.; Hart, G.W. Diabetes-associated dysregulation of O-GlcNAcylation in rat cardiac mitochondria. Proc Natl Acad Sci USA. 2015, 112, 6050-6055.


Page 27 of 42

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


27. Ma, J.; Liu, T.; Wei, A.C.; Banerjee, P.; O’Rourke, B.; Hart, G. O-GlcNAcomics reveals widespread O-GlcNAcylation regulating cardiac mitochondrial functions. J Biol Chem 2015, 290, 29141-29153. 28. Akimoto, Y.; Kreppel, L.K.; Hirano, H.; Hart GW. Increased O-GlcNAc transferase in pancreas of rats with streptozotocin-induced diabetes. Diabetologia. 2000, 43,1239-1247. 29. Foster, D.B.; Rucker, J.J.; Marban, E. Is Kir6.1 a subunit of mitoKATP? Biochem Biophys Research Comm. 2008, 366, 649-656. 30. Aon, M.A.; Stanley, B.A.; Sivakumaran, V.; Kembro, J.M.; O'Rourke, B.; Paolocci, N.; Cortassa, S. Glutathione/thioredoxin systems modulate mitochondrial H2O2 emission: An experimental-computational study. J Gen Physio 2012, 139, 479-491. 31. Wei, A.C.; Liu, T.; Cortassa, S.; Winslow, R.L.; O'Rourke, B. Mitochondrial Ca2+ influx and efflux rates in guinea pig cardiac mitochondria: low and high affinity effects of cyclosporine A. Biochim Biophys Acta 2011, 1813, 1373-1381. 32. Baycin-Hizal, D.; Tabb, D.L.; Chaerkady, R.; Chen, L.; Lewis, N.E.; Nagarajan, H.; Sarkaria, V.; Kumar, A.; Wolozny, D.; Colao, J.; Jacobson, E.; Tian, Y.; O'Meally, R.N.; Krag, S.S.; Cole, R.N.; Palsson, B.O.; Zhang, H.; Betenbaugh, M. Proteomic analysis of Chinese hamster ovary cells. J Proteome Res 2012,11, 5265-5276. 33. Wells, L.; Vosseller, K.; Cole, R.N.; Cronshaw, J.M.; Matunis, M.J.; Hart, G.W. Mapping sites of O-GlcNAc modification using affinity tags for serine and threonine post-translational modifications. Mol Cell Proteomics 2002, 1, 791-804. 34. Vosseller, K.; Hansen, K.C.; Chalkley, R.J. Trinidad, J.C.; Wells, L.; Hart, G.W.; Burlingame, A.L. Quantitative analysis of both protein expression and serine/threonine post-translational modifications through stable isotope labeling with dithiothreitol. Proteomics 2005, 5, 388-398. 35. Overath, T.; Kuckelkorn, U.; Henklein, P.; Strehl, B.; Bonar, D.; Kloss, A.; Siele, D.; Kloetzel, P.M.; Janek. K. Mapping of O-GlcNAc sites of 20S proteasome subunits and Hsp90 by a novel biotin-cystamine tag. Mol Cell Proteomics 2012, 11, 467-477.



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 28 of 42

36. Tabb, D.L.; Friedman, D.B.; Ham, A-J.L. Verification of automated peptide identifications from proteomic tandem mass spectra. Nature Prot 2006, 1, 2213-2222. 37. Emanuelsson, O.; Nielsen, H.; Brunak, S.; von Heijne, G. Predicting subcellular localization of proteins based on their N-terminal amino acid sequence. J Mol Biol 2000, 300, 1005-1016. 38. Claros, M.G.; Vincens, P. Computational method to predict mitochondrially imported proteins and their targeting sequences. Eur J Biochem 1996, 241, 779-786. 39. Small, I.; Peeters ,N.; Legeai, F.; Lurin, C. Predotar: A tool for rapidly screening proteomes for N-terminal targeting sequences. Proteomics 2004, 4, 1581-1590. 40. Crooks, G.E.; Hon, G.; Chandonia, J.M.; Brenner, S.E. WebLogo: A Sequence Logo Generator. Genome Res. 2004, 14, 1188-1190. 41. Marciniak, C.; Marechal, X.; Montaigne, D.; Neviere, R.; Lancel, S. Cardiac contractile function and mitochondrial respiration in diabetes-related mouse models. Cardiovasc Diabetol. 2014, 13, 118. 42. Loiselle, D.S.; Han, J.; Mellor, K.M.; Pham, T.; Tran K.; Goo, S.; Taberner A.J.; Hickey, A.J.R. Assessing the Efficiency of the Diabetic Heart at Subcellular, Tissue and Organ Level. J Gen Pract. 2014, 2, 168. 43. Sloan, R.C.; Moukdar, F.; Frasier, C.R.; Patel, H.D.; Bostian, P.A.; Lust, R.M.; Brown, D.A. Mitochondrial permeability transition in the diabetic heart: contributions of thiol redox state and mitochondrial calcium to augmented reperfusion injury. J Mol Cell Cardiol. 2012, 52, 1009-1018. 44. Buchanan, J.; Mazumder, P.K.; Hu, P.; Chakrabarti, G.; Roberts, M.W.; Yun, U.J.; Cooksey, R.C.; Litwin, S.E.; Abel, E.D. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 2005, 146, 5341-5349.


Page 29 of 42

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


45. Son, N.H.; Park, T.S.; Yamashita, H.; Yokoyama, M.; Huggins, L.A.; Okajima, K.; Homma, S.; Szabolcs, M.J.; Huang, L.S.; Goldberg, I.J. Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J Clin Invest. 2007, 117, 2791-1801. 46. Prosdocimo, D.A.; Anand, P.; Liao, X.; Zhu, H.; Shelkay, S.; Artero-Calderon, P.; Zhang, L.; Kirsh, J.; Moore, D.; Rosca, M.G.; Vazquez, E.; Kerner, J.; Akat, K.M.; Williams, Z.; Zhao, J.; Fujioka, H.; Tuschl, T.; Bai, X.; Hoppel, C.L.; Jain, M.K.; Haldar, S.M. Kruppel-like factor 15 is a critical regulator of cardiac lipid metabolism. J Biol Chem. 2014, 289, 5914-5924. 47. Finck, B.N.; Lehman, J.J.; Leone, T.C.; Welch, M.J.; Bennett, M.J.; Kovacs, A.; Han, X.; Gross, R.W.; Kozak, R.; Lopaschuk, G.D.; Kelly, D.P. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest. 2002, 109, 121-130. 48. Ow, S. Y.; Salim, M.; Noirel, J.; Evans, C.; Wright, P. C. Minimising iTRAQ ratio compression through understanding LC-MS elution dependence and high-resolution HILIC fractionation. Proteomics 2011, 11, 2341-2346. 49. Turko, I.V.; Murad, F. Quantitative protein profiling in heart mitochondria from diabetic rats. J Biol Chem. 2003, 278, 35844-35849. 50. Hamblin, M.; Friedman, D.B.; Hill, S.; Caprioli, R.M.; Smith, H.M.; Hill, M.F. Alterations in the diabetic myocardial proteome coupled with increased myocardial oxidative stress underlies diabetic cardiomyopathy. J Mol Cell Cardiol. 2007, 42, 884-895. 51. Brookes, P.S.; Pinner, A.; Ramachandran, A.; Coward, L.; Barnes, S.; Kim, H.; DarleyUsmar, V. High throughput two-dimensional blue-native electrophoresis: A tool for functional proteomics of mitochondria and signaling complexes. Proteomics 2002, 2, 969-977. 52. Butkinaree, C.; Park, K.; Hart, G.W. O-linked beta-N-acetylglucosamine (O-GlcNAc): Extensive crosstalk with phosphorylation to regulate signaling and transcription in response to nutrients and stress. Biochim Biophys Acta. 2010, 1800, 96-106. 53. Dias, W.B.; Cheung, W.D.; Hart, G.W. O-GlcNAcylation of kinases. Biochem Biophys Res



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 30 of 42

Commun 2012, 422, 224-228. 54. Linn, T.C.; Pettit, F.H.; Reed, L.J. Alpha-keto acid dehydrogenase complexes. X. Regulation of the activity of the pyruvate dehydrogenase complex from beef kidney mitochondria by phosphorylation and dephosphorylation. Proc Natl Acad Sci U S A. 1969, 62, 234-241. 55. Rao, F.V.; Dorfmueller, H.C.; Villa, F.; Allwood, M.; Eggleston, I.M.; van Aalten, D.M. Structural insights into the mechanism and inhibition of eukaryotic O-GlcNAc hydrolysis. EMBO J. 2006, 25, 1569-1578. 56. Patel, M.S.; Korotchkina, LG. Regulation of the pyruvate dehydrogenase complex. Biochem Soc Trans. 2006, 34, 217-222. 57. Hart, G.W.; Copeland, R.J. Glycomics hits the big time. Cell 2010, 143, 672-676. 58. Ardail, D.; Louisot, P.; Levrat, C. Characterization of the submitochondrial compartments: study of the site of synthesis of dolichol and dolichol-linked sugars. Biochem Biophys Res Commun. 1989, 164, 1009-1017. 59. Chandra, N.C.; Spiro, M.J.; Spiro, R.G. Identification of a glycoprotein from rat liver mitochondrial inner membrane and demonstration of its origin in the endoplasmic reticulum. J Biol Chem. 1998, 273, 19715-19721. 60. Kung, L.A.; Tao, S.C.; Qian, J.; Smith, M.G.; Snyder, M.; Zhu, H. Global analysis of the glycoproteome in Saccharomyces cerevisiae reveals new roles for protein glycosylation in eukaryotes. Mol Syst Biol. 2009, 5, 308.


Page 31 of 42

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Figure 1. Impaired cardiac mitochondrial function in diabetic hearts. Mitochondrial oxygen consumption rates were determined with the presence of glutamate/malate (G/M; A) and succinate (Succ.; B). State 4: without the addition of ADP; State 3: with the addition of ADP. Mitochondrial membrane potential (C-D) was determined with either glutamate/malate (C) or succinate (D). Respiratory control ratios (RCRs) of isolated mitochondria were determined from the rates of State 3 and State 4 oxygen consumption in the presence of G/M (E). (F) Calculated Ca2+ uptake capacity prior to permeability transition pore opening in mitochondria isolated from control and diabetic rats. (N ≥ 4; the 2-tailed unpaired Student t test was used to compare different groups, with p < 0.05 being considered significant.)

Figure 2. Altered abundance of proteins in several major metabolic pathways in mitochondria between control and diabetic hearts. Proteins with decreased abundance are shown in green, proteins with increased abundance are shown in red, while proteins without apparent changes are shown in blue. HK, hexokinase-1; MPC, mitochondrial pyruvate carrier 1; PDH, pyruvate dehydrogenase; PDC, pyruvate dehydrogenase complex;

PDK4,

pyruvate

dehydrogenase

kinase

4;

CPT1,

carnitine

O-

palmitoyltransferase 1; ACADL, very long-chain specific acyl-CoA dehydrogenase; ECHS, enoyl-CoA hydratase, mitochondrial precursor; HADHA, trifunctional enzyme subunit alpha; HADHB, trifunctional enzyme subunit beta; CS, citrate synthase; ACO2, aconitate

hydratase;

IDH,

isocitrate

dehydrogenase;

OGDH,

2-oxoglutarate

dehydrogenase; SUCLA2, succinyl-CoA ligase; SDHA; succinate dehydrogenase A; 31 ACS Paragon Plus Environment


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 32 of 42

SDHB, succinate dehydrogenase B; MDH, malate dehydrogenase; FUM, fumarate hydratase.

Figure 3. O-GlcNAcylation occurs on many mitochondria proteins. Highly purified cardiac mitochondrial proteins from control rats (A) and diabetic rats (B) were separated with two-dimensional gel (IEF/SDS-PAGE), transferred to PVDF membranes and immunoblotted with CTD 110.6.

Figure 4. O-GlcNAcylated proteins are involved in multiple mitochondrial pathways. OGlcNAcylated proteins are shown in red, with number of sites shown in parenthesis. PDH, pyruvate dehydrogenase; CPT1, carnitine O-palmitoyltransferase 1; CPT2, carnitine O-palmitoyltransferase 2; ACADL, very long-chain specific acyl-CoA dehydrogenase; ECHS, enoyl-CoA hydratase, mitochondrial precursor; HADHA, trifunctional enzyme subunit alpha; HADHB, trifunctional enzyme subunit beta; CS, citrate synthase; ACO2, aconitate hydratase; IDH, isocitrate dehydrogenase; OGDH, 2oxoglutarate

dehydrogenase;

SUCLA2,

succinyl-CoA

ligase;

SDHA;

succinate

dehydrogenase A; SDHB, succinate dehydrogenase B; MDH, malate dehydrogenase; FUM, fumarate hydratase; CI, complex I; CII, complex II; CIII, complex III; CIV, complex IV; CV, complex V; SLC24A4, ADP/ATP translocase 1; SLC25A3, phosphate carrier protein; MCU, mitochondrial Ca2+ uniporter; VDAC1/2, voltage-dependent anionselective channel protein 1/2; SOD2, superoxide dismutase [Mn]; PRDX3, thioredoxindependent peroxide reductase; HSP60, 60 kDa heat shock protein; SAM50, sorting and


Page 33 of 42

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


assembly machinery component 50 homolog; CKMT2, creatine kinase S-type, mitochondrial precursor. Please refer to Table S2 for detailed description of the corresponding O-GlcNAc peptides.

Figure 5. Site-specific O-GlcNAc dynamics on enzymes in pyruvate decarboxylation and TCA cycle (A) and fatty acid utilization (B) in control and diabetic hearts. Only proteins with ≥ 2 O-GlcNAc sites were shown. The dashed line denotes an ROR = 1. PDHA1, pyruvate dehydrogenase subunit alpha; DLAT, dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex; CPT1B, carnitine Opalmitoyltransferase 1, muscle isoform; HADHA, trifunctional enzyme subunit alpha; HADHB, trifunctional enzyme subunit beta; ACO2, aconitate hydratase; SDHA; succinate dehydrogenase A.

Figure 6. Validation of O-GlcNAcylation of PDHA1 in cardiac mitochondria from control and diabetic rats. Pyruvate dehydrogenase complexes were immunopurified from lysates of cardiac mitochondria from control and diabetic rats. After extensively washing, the immunoprecipitates were treated with or without CpNag J as indicated, then separated with SDS-PAGE, and transferred to PVDF membranes for blotting with PDHA1 and RL2. Blots in the presence of 1 M GlcNAc were used as a competitive assay.



Fig. 1 B 200

Control, G/M Diabetes, G/M

**

150

100

50

0

Oxygen consumption rate (nmole/min/mg)

A Oxygen consumption rate (nmole/min/mg)

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42

Page 34 of 42

300 250

Control, Succ. Diabetes, Succ.

200 150 100 50 0

State 4

State 4

State 3

ACS Paragon Plus Environment

State 3

Page 35 of 42

Fig. 1

D

C 200

G/M

ADP

Control Diabetes

KCN

190

KCN

Control Diabetes

KCN

190

ΔΨ m(mV)

DNP

Succ ADP

200

180

ΔΨ m(mV)

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42


DNP

170

180

DNP

170

160

160

150

150

-100 0 100 200 300 400 500 600 700 800 900

0

200

400

600

800 1000 1200 1400

Time (s)

Time (s)


KCN DNP


Fig. 1

10 8 6 4 2

Control Diabetes

n.s.

Mitochondria Ca2+ capacity (nmolemg)

F

E

RCR (OCRState 3 / OCRState 4)

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42

Page 36 of 42

0


800 700 600 500 400 300 200 100 0

Control Diabetes

*

Page 37 of 42

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42


Fig. 2 Glucose

Fatty acid

HK1

CPT1

pyruvate MPC1

Acyl CoA

pyruvate PDK4

ACADL ECHS1 FAO HADHB HADHA

PDC Ac-CoA

Matrix

CS ACO

FUM

MDH

TCA cycle

SDHA SDHB

IDH

OGDH SUCLA2



Fig. 3 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42

3

A 225

IEF

10

Control IB: 110.6

SDSPAGE

12

B

225

Page 38 of 42

Diabetes IB: 110.6

SDSPAGE


Page 39 of 42

Fig. 4

Fatty acid

Pyruvate

CPT1

PCr

(3)

CKMT2

CPT2

Matrix

PDH (3) Ac-CoA

FAO CS FH

SDHA/B (3)

SUCLA2 (1)

H+ (26 in

(4 in 12 subunits) 2 subunits)

CI

CII

I

IDH3A/3B (2)

Redox

H+ (8 in 5 subunits)

CIII

PRDX3

(4 in 3 subunits)

ATP

CV

H+

OxPhos

SLC25 A4

ATP

CIV


(1)

Ca2+ (2) Regulation

ADP + Pi H+

SAM50

HSP60 (2)

ECHS1 (2)

SOD2 (1)

OGDH (1)

Assembly and import

VDAC1/2

TCA

MDH2 (2)

HADHA (3)

ACO2 (4)

(7)

Cr

Acyl CoA ACADL HADHB (2) (4)

Pyruvate

MCU

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42


Ca2+

mPTP

(3)

(29 in 8 subunits)

SLC25 A3

(1)

Pi

Fig. 5 A

ROR (Diabetes/Control)

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42


1.0

1.2

1.0

1.0

0.8

1.6 1.4

0.8

1.2 0.6

0.8 0.6

0.8 0.4

0.4

0.6

0.4

0.4

0.2

S293

S232

0.0

0.2

0.2

0.2 0.0

0.6

1.0

S411

PDHA1

S524

0.0

S35

T256 S420 S562

DLAT

B

ROR (Diabetes/Control)

Page 40 of 42

0.0

S191

ACO2

S497

S513

SDHA

1.6

1.4

1.8 1.4

1.2

1.6

1.2

1.4

1.0

1.2

0.8

1.0

1.0 0.8 0.6

0.8

0.6

0.4

0.6

0.4

0.2

0.2

0.0

0.0

S180 S191 CPT1B

S408

0.4 0.2

T185 T269

S615


HADHA

0.0

T70 S86

S127 S238

HADHB

Page 41 of 42

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Input 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42


Fig. 6 PDC

+ CpNag J

-

Control Control + CpNag J Diabetes

Diabetes

-

IB: O-GlcNAc on PDHA1 IB: O-GlcNAc on PDHA1 + 1 M GlcNAc

IB: PDHA1

Relative O-GlcNAc level (normalized to control)

Control

1.5

** 1.0

0.5

0.0


*


Table of contents synopsis (for TOC only) (O4GlcNAcylated" proteins"are"shown" in"red)"

Fatty acid

Pyruvate

CPT1"

PCr

""

CKMT2

CPT2" Pyruvate

Matrix

PDH HADHB

Ac-CoA

FAO CS

TCA

Redox

ECHS1

PRDX3

SOD2

OGDH

SDHA/B

ATP

SUCLA2 H+

H+ CI

CII"

CIII

SAM50

HSP60 ""

""

Ca2+ Regulation

I"

IDH3A/3B

Assembly and import

H+

SLC25 A4

ATP

ADP + Pi CV

CIV

VDAC1/2"

MDH2

HADHA

ACO2

FH

""

Cr

Acyl CoA ACADL

MCU"

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 42 of 42

Ca2+

mPTP

"" SLC25" "A3"

""

Pi

H+

OxPhos

By performing global profiling of O-GlcNAcylation in functional mitochondria in control and diabetic hearts, we identified and quantified 86 O-GlcNAcylated mitochondrial proteins, including multiple enzymes in major metabolic pathways (including the TCA cycle, and fatty acid oxidation).


Comparative Proteomics Reveals Dysregulated Mitochondrial O

Recommend Documents